交易 Teva Pharma Ind Adr Rep 1 - TEVA CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.20 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.030779% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | -0.013666% | ||||||||
隔夜费时间 | 22:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Teva Pharmaceutical Industries Ltd ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 10.67 | 0.16 | 1.52% | 10.51 | 10.76 | 10.51 |
Feb 2, 2023 | 10.66 | 0.09 | 0.85% | 10.57 | 10.68 | 10.47 |
Feb 1, 2023 | 10.56 | 0.11 | 1.05% | 10.45 | 10.64 | 10.35 |
Jan 31, 2023 | 10.39 | 0.18 | 1.76% | 10.21 | 10.67 | 10.21 |
Jan 30, 2023 | 10.21 | 0.07 | 0.69% | 10.14 | 10.36 | 10.05 |
Jan 27, 2023 | 10.24 | 0.10 | 0.99% | 10.14 | 10.48 | 10.14 |
Jan 26, 2023 | 10.23 | 0.09 | 0.89% | 10.14 | 10.27 | 10.07 |
Jan 25, 2023 | 10.15 | 0.11 | 1.10% | 10.04 | 10.19 | 10.02 |
Jan 24, 2023 | 10.05 | -0.16 | -1.57% | 10.21 | 10.32 | 10.05 |
Jan 23, 2023 | 10.33 | 0.02 | 0.19% | 10.31 | 10.43 | 10.20 |
Jan 20, 2023 | 10.21 | -0.30 | -2.85% | 10.51 | 10.59 | 10.21 |
Jan 19, 2023 | 10.47 | 0.00 | 0.00% | 10.47 | 10.62 | 10.23 |
Jan 18, 2023 | 10.80 | 0.00 | 0.00% | 10.80 | 10.90 | 10.68 |
Jan 17, 2023 | 10.95 | -0.15 | -1.35% | 11.10 | 11.21 | 10.92 |
Jan 13, 2023 | 11.18 | -0.01 | -0.09% | 11.19 | 11.27 | 10.94 |
Jan 12, 2023 | 11.26 | 0.19 | 1.72% | 11.07 | 11.41 | 11.02 |
Jan 11, 2023 | 10.96 | 0.02 | 0.18% | 10.94 | 11.14 | 10.82 |
Jan 10, 2023 | 10.88 | 0.06 | 0.55% | 10.82 | 11.01 | 10.75 |
Jan 9, 2023 | 10.78 | -0.05 | -0.46% | 10.83 | 11.19 | 10.58 |
Jan 6, 2023 | 10.46 | 0.49 | 4.91% | 9.97 | 10.69 | 9.89 |
Teva Pharma Ind Adr Rep 1 Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- 年度
- 每季度
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
总收入 | 21903 | 22385 | 18854 | 16887 | 16659 | 15878 |
收入 | 21903 | 22385 | 18854 | 16887 | 16659 | 15878 |
收入成本,共计 | 10250 | 11770 | 10558 | 9351 | 8870 | 8014 |
毛利 | 11653 | 10615 | 8296 | 7536 | 7789 | 7864 |
总营业费用 | 20631 | 39911 | 20537 | 17330 | 20231 | 14162 |
销售/一般/行政费用,总计 | 4973 | 4637 | 4052 | 3667 | 3519 | 3402 |
研究与开发 | 2077 | 1778 | 1213 | 1010 | 997 | 967 |
异常费用(收入) | 3286 | 21520 | 4838 | 3191 | 6739 | 1721 |
Other Operating Expenses, Total | 45 | -3 | -286 | -28 | -20 | -41 |
营业收入 | 1272 | -17526 | -1683 | -443 | -3572 | 1716 |
利息收入(费用),非经营净值 | -446 | -856 | -894 | -825 | -833 | -988 |
其他,净值 | -2 | 3 | -19 | 3 | -1 | -70 |
税前净收入 | 824 | -18379 | -2596 | -1265 | -4406 | 658 |
税后净收入 | 303 | -17507 | -2304 | -987 | -4238 | 447 |
少数股东权益 | 18 | 184 | 322 | 2 | 109 | -39 |
Equity In Affiliates | 8 | -3 | -71 | -13 | 138 | 9 |
未计算非常项目前的净收益 | 329 | -17326 | -2053 | -998 | -3991 | 417 |
非常规项目总计 | 0 | 1061 | -97 | 0 | 0 | |
净收入 | 329 | -16265 | -2150 | -998 | -3991 | 417 |
Total Adjustments to Net Income | -261 | -260 | -249 | -1 | 1 | |
普通股股东可获收益 (不含非经常性项目) | 68 | -17586 | -2302 | -999 | -3990 | 417 |
普通股股东可获收益 (含非經常性項目) | 68 | -16525 | -2399 | -999 | -3990 | 417 |
摊薄调整 | 0 | |||||
摊薄净收入 | 68 | -16525 | -2399 | -999 | -3990 | 417 |
摊薄后加权平均股 | 961 | 1016 | 1021 | 1091 | 1095 | 1107 |
扣除特别项目的每股摊薄盈利 | 0.07076 | -17.3091 | -2.25465 | -0.91567 | -3.64384 | 0.37669 |
Dividends per Share - Common Stock Primary Issue | 1.36 | 0.85 | 0 | |||
每股正常摊薄盈利 | 2.29537 | -3.51127 | 0.82537 | 0.98547 | 0.35648 | 1.43282 |
Depreciation / Amortization | 209 | 162 | 139 | 126 | 99 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
总收入 | 3982 | 3910 | 3887 | 4100 | 3661 |
收入 | 3982 | 3910 | 3887 | 4100 | 3661 |
收入成本,共计 | 2063 | 1987 | 1989 | 1975 | 1859 |
毛利 | 1919 | 1923 | 1898 | 2125 | 1802 |
总营业费用 | 3548 | 3328 | 3264 | 4022 | 4374 |
销售/一般/行政费用,总计 | 848 | 832 | 864 | 858 | 819 |
研究与开发 | 254 | 243 | 222 | 249 | 225 |
Depreciation / Amortization | 27 | 25 | 24 | 23 | 22 |
异常费用(收入) | 360 | 247 | 183 | 893 | 1502 |
Other Operating Expenses, Total | -4 | -6 | -18 | 24 | -53 |
营业收入 | 434 | 582 | 623 | 78 | -713 |
利息收入(费用),非经营净值 | -381 | -254 | -254 | -170 | -238 |
其他,净值 | 91 | -20 | 13 | -83 | -20 |
税前净收入 | 144 | 308 | 382 | -175 | -971 |
税后净收入 | 82 | 210 | 306 | -151 | -973 |
少数股东权益 | -7 | -14 | -11 | -7 | -3 |
Equity In Affiliates | 3 | 11 | -5 | 0 | 21 |
未计算非常项目前的净收益 | 78 | 207 | 290 | -158 | -955 |
净收入 | 78 | 207 | 290 | -158 | -955 |
Total Adjustments to Net Income | -1 | 2 | -1 | ||
普通股股东可获收益 (不含非经常性项目) | 77 | 207 | 292 | -159 | -955 |
普通股股东可获收益 (含非經常性項目) | 77 | 207 | 292 | -159 | -955 |
摊薄净收入 | 77 | 207 | 292 | -159 | -955 |
摊薄后加权平均股 | 1107 | 1109 | 1109 | 1102 | 1107 |
扣除特别项目的每股摊薄盈利 | 0.06956 | 0.18665 | 0.2633 | -0.14428 | -0.86269 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | 0.25474 | 0.33851 | 0.39548 | 0.38244 | 0.01924 |
- 年度
- 每季度
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
流动资产总额 | 17228 | 15382 | 13794 | 13464 | 13005 | 12573 |
现金和短期投资 | 1667 | 977 | 1784 | 1975 | 2177 | 2165 |
现金等价物 | 988 | 963 | 1782 | 1975 | 2177 | 2165 |
短期投资 | 679 | 14 | 2 | |||
应收账款总额,净额 | 7523 | 7128 | 5822 | 5676 | 4581 | 4529 |
Accounts Receivable - Trade, Net | 7523 | 7128 | 5822 | 5676 | 4581 | 4529 |
Total Inventory | 4954 | 4924 | 4731 | 4422 | 4403 | 3818 |
Prepaid Expenses | 1629 | 1100 | 899 | 870 | 945 | 1075 |
Other Current Assets, Total | 1455 | 1253 | 558 | 521 | 899 | 986 |
Total Assets | 93057 | 70615 | 60683 | 57470 | 50640 | 47666 |
Property/Plant/Equipment, Total - Net | 8073 | 7673 | 6868 | 6950 | 6855 | 6477 |
Property/Plant/Equipment, Total - Gross | 11926 | 12178 | 11796 | 11864 | 11947 | 11718 |
Accumulated Depreciation, Total | -3853 | -4505 | -4928 | -4914 | -5092 | -5241 |
Goodwill, Net | 44409 | 28414 | 24917 | 24846 | 20624 | 20040 |
Intangibles, Net | 21487 | 17640 | 14005 | 11232 | 8923 | 7466 |
Other Long Term Assets, Total | 1860 | 1423 | 1038 | 978 | 1233 | 1110 |
Total Current Liabilities | 18488 | 17921 | 14322 | 13674 | 13164 | 11027 |
Accounts Payable | 2157 | 2069 | 1853 | 1718 | 1756 | 1686 |
Accrued Expenses | 4264 | 3563 | 2738 | 2680 | 2581 | 2880 |
Notes Payable/Short Term Debt | 2466 | 766 | 516 | 514 | 514 | 23 |
Current Port. of LT Debt/Capital Leases | 810 | 2880 | 1700 | 1831 | 2674 | 1403 |
Other Current Liabilities, Total | 8791 | 8643 | 7515 | 6931 | 5639 | 5035 |
Total Liabilities | 59720 | 53256 | 45976 | 43498 | 40614 | 37388 |
Total Long Term Debt | 32522 | 28827 | 26691 | 24562 | 22731 | 21617 |
Long Term Debt | 32522 | 28827 | 26691 | 24562 | 22731 | 21617 |
Deferred Income Tax | 5413 | 3277 | 2140 | 1096 | 964 | 784 |
Minority Interest | 1656 | 1386 | 1087 | 1091 | 1035 | 966 |
Other Liabilities, Total | 1641 | 1845 | 1736 | 3075 | 2720 | 2994 |
Total Equity | 33337 | 17359 | 14707 | 13972 | 10026 | 10278 |
Redeemable Preferred Stock | 3620 | 3631 | 0 | |||
Common Stock | 54 | 54 | 56 | 56 | 57 | 57 |
Additional Paid-In Capital | 23409 | 23479 | 27210 | 27312 | 27443 | 27561 |
Retained Earnings (Accumulated Deficit) | 13607 | -3803 | -5958 | -6956 | -10946 | -10529 |
Treasury Stock - Common | -4194 | -4149 | -4142 | -4128 | -4128 | -4128 |
Unrealized Gain (Loss) | -7 | -4 | 1 | 0 | 0 | 0 |
Other Equity, Total | -3152 | -1849 | -2460 | -2312 | -2400 | -2683 |
Total Liabilities & Shareholders’ Equity | 93057 | 70615 | 60683 | 57470 | 50640 | 47666 |
Total Common Shares Outstanding | 1014.99 | 1016.88 | 1089.39 | 1092.19 | 1096.51 | 1103.33 |
Total Preferred Shares Outstanding | 3.7 | 3.7 | 0 | 0 | 0 | |
Long Term Investments | 83 | 61 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 12401 | 12822 | 12154 | 12573 | 12451 |
现金和短期投资 | 1743 | 2436 | 2045 | 2165 | 2175 |
现金等价物 | 1743 | 2436 | 2045 | 2165 | 2175 |
应收账款总额,净额 | 4572 | 4488 | 4046 | 4529 | 4253 |
Accounts Receivable - Trade, Net | 4572 | 4488 | 4046 | 4529 | 4253 |
Total Inventory | 4406 | 4362 | 4167 | 3818 | 4012 |
Prepaid Expenses | 942 | 1022 | 1066 | 1075 | 1064 |
Other Current Assets, Total | 738 | 514 | 830 | 986 | 947 |
Total Assets | 49004 | 49195 | 47851 | 47666 | 47059 |
Property/Plant/Equipment, Total - Net | 6641 | 6658 | 6547 | 6477 | 6396 |
Goodwill, Net | 20302 | 20421 | 20179 | 20040 | 19986 |
Intangibles, Net | 8445 | 8120 | 7832 | 7466 | 7116 |
Other Long Term Assets, Total | 1215 | 1174 | 1139 | 1110 | 1110 |
Total Current Liabilities | 12089 | 12691 | 11825 | 11027 | 11613 |
Accounts Payable | 1692 | 1551 | 1514 | 1686 | 1750 |
Accrued Expenses | 2377 | 2318 | 2590 | 2771 | 3078 |
Notes Payable/Short Term Debt | 23 | 23 | 323 | 23 | 23 |
Current Port. of LT Debt/Capital Leases | 2674 | 3507 | 2386 | 1403 | 2054 |
Other Current Liabilities, Total | 5323 | 5292 | 5012 | 5144 | 4708 |
Total Liabilities | 39004 | 38871 | 37384 | 37388 | 37715 |
Total Long Term Debt | 22288 | 21602 | 21037 | 21617 | 20840 |
Long Term Debt | 22288 | 21602 | 21037 | 21617 | 20840 |
Deferred Income Tax | 991 | 932 | 910 | 784 | 666 |
Minority Interest | 975 | 987 | 984 | 966 | 916 |
Other Liabilities, Total | 2661 | 2659 | 2628 | 2994 | 3680 |
Total Equity | 10000 | 10324 | 10467 | 10278 | 9344 |
Common Stock | 57 | 57 | 57 | 57 | 57 |
Additional Paid-In Capital | 27474 | 27503 | 27529 | 27561 | 27587 |
Retained Earnings (Accumulated Deficit) | -10869 | -10662 | -10370 | -10529 | -11484 |
Treasury Stock - Common | -4128 | -4128 | -4128 | -4128 | -4128 |
Other Equity, Total | -2534 | -2446 | -2621 | -2683 | -2688 |
Total Liabilities & Shareholders’ Equity | 49004 | 49195 | 47851 | 47666 | 47059 |
Total Common Shares Outstanding | 1102.35 | 1102.89 | 1103.01 | 1103.33 | 1110.35 |
Total Preferred Shares Outstanding | 0 | ||||
Unrealized Gain (Loss) | 0 |
- 年度
- 每季度
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
净收入/起跑线 | 311 | -16449 | -2472 | -1000 | -4099 | 456 |
经营活动产生的现金 | 3890 | 2225 | 2446 | 748 | 1216 | 798 |
经营活动产生的现金 | 1524 | 2112 | 1842 | 1722 | 1557 | 1330 |
Deferred Taxes | 15 | -2331 | -837 | -985 | -696 | -120 |
非现金物品 | 2156 | 20538 | 5736 | 1907 | 6642 | 833 |
Cash Taxes Paid | 341 | 106 | 420 | 552 | 709 | 495 |
已付现金利息 | 290 | 795 | 815 | 840 | 846 | 913 |
营运资金的变化 | -116 | -1645 | -1823 | -896 | -2188 | -1701 |
投资活动产生的现金 | -34405 | 3446 | 1866 | 1355 | 863 | 1523 |
资本支出 | -901 | -874 | -651 | -525 | -578 | -562 |
其他投资现金流量项目,总计 | -33504 | 4320 | 2517 | 1880 | 1441 | 2085 |
融资活动产生的现金 | 25217 | -5750 | -3351 | -1926 | -1885 | -2172 |
融资现金流项目 | -169 | -112 | -57 | -11 | -5 | -6 |
Total Cash Dividends Paid | -1558 | -1161 | -22 | -52 | 0 | 0 |
股票的发行(报废),净额 | 693 | 0 | 0 | |||
债务的发行(退还),净额 | 26251 | -4477 | -3272 | -1863 | -1880 | -2166 |
外汇效应 | -660 | 54 | -142 | 16 | 8 | -128 |
现金净变化 | -5958 | -25 | 819 | 193 | 202 | 21 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 84 | 306 | 608 | 456 | -952 |
Cash From Operating Activities | -405 | -187 | 342 | 798 | -49 |
Cash From Operating Activities | 376 | 681 | 1010 | 1330 | 323 |
Deferred Taxes | -11 | 5 | 13 | -120 | -175 |
Non-Cash Items | 222 | 500 | 592 | 833 | 196 |
Changes in Working Capital | -1076 | -1679 | -1881 | -1701 | 559 |
Cash From Investing Activities | 508 | 989 | 1277 | 1523 | 161 |
Capital Expenditures | -150 | -263 | -409 | -562 | -157 |
Other Investing Cash Flow Items, Total | 658 | 1252 | 1686 | 2085 | 318 |
Cash From Financing Activities | -493 | -494 | -1671 | -2172 | 2 |
Financing Cash Flow Items | -2 | -3 | -5 | -6 | 2 |
Issuance (Retirement) of Debt, Net | -491 | -491 | -1666 | -2166 | 0 |
Foreign Exchange Effects | -44 | -49 | -80 | -128 | -62 |
Net Change in Cash | -434 | 259 | -132 | 21 | 52 |
Total Cash Dividends Paid | 0 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Capital Research Global Investors | Investment Advisor | 10.5524 | 117190328 | 24024045 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.5415 | 39329765 | 39329765 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.8455 | 31600577 | -827744 | 2022-09-30 | LOW |
Abrams Capital, L.L.C. | Hedge Fund | 2.152 | 23899296 | -147060 | 2022-09-30 | LOW |
Menora Mivtachim Insurance Ltd. | Insurance Company | 2.0987 | 23307560 | -3050 | 2022-09-30 | LOW |
Migdal Insurance and Financial Holdings Ltd | Insurance Company | 1.9447 | 21596560 | 216360 | 2022-12-31 | MED |
Phoenix Holdings Ltd | Holding Company | 1.8757 | 20831080 | 2301291 | 2022-09-30 | MED |
Clal Insurance Enterprises Holdings Ltd. | Investment Advisor | 1.7475 | 19406766 | 444000 | 2022-09-30 | LOW |
Harel Insurance Investments and Financial Services Ltd | Investment Advisor | 1.3613 | 15118229 | 985502 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3418 | 14901933 | 1055920 | 2022-09-30 | LOW |
EXOR Investments (UK) LLP | Investment Advisor | 1.0375 | 11522187 | 11522187 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.9613 | 10675231 | -7647 | 2022-09-30 | LOW |
Miller Value Partners, LLC | Investment Advisor | 0.8334 | 9254875 | -79715 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7338 | 8148857 | 126299 | 2022-09-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.7189 | 7983801 | 5844332 | 2022-09-30 | HIGH |
Beck, Mack & Oliver LLC | Investment Advisor | 0.6787 | 7536985 | 1072190 | 2022-09-30 | LOW |
Camber Capital Management LP | Hedge Fund | 0.6753 | 7500000 | 4750000 | 2022-09-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5973 | 6633114 | 314715 | 2022-09-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4259 | 4730246 | -881152 | 2022-09-30 | LOW |
Schweizerische Nationalbank | Bank and Trust | 0.4247 | 4716093 | 27700 | 2022-09-30 | LOW |
为什么选择 Capital.com?让我们的数字来说话。
Capital.com Group交易計算器
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
貿易佣金
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
杠杆
20:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Teva Company profile
关于 Teva Pharmaceutical Industries Ltd (ADR)
梯瓦制药工业有限公司是一家位于以色列的制药公司。 该公司通过三个部分运营。 北美、欧洲和国际市场。 每个业务部门管理其所在地区的全部产品组合,包括非专利药、专业药和非处方药(OTC)产品。 除了这三个部分,公司还有其他业务,主要是向第三方销售活性药物成分(API),某些合同生产服务,以及通过其关联公司Medis向其他制药公司提供产品组合的对外授权平台。
Industry: | Pharmaceuticals (NEC) |
5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球485,000万多名交易者的一份子,选择利用Capital.com进行交易吧。